LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ChromaDex–ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023. Second Quarter 2023 and Recent Highlights Total net sales were $20.3 million, with $16.9 million from Tru Niagen®, up 21% and 16% from the prior year quarter, respectively. Strong gross margin of 60.8%…
Click here to view original post
Copyright © 2023 Biotech Networks, LLC
